A Study to Evaluate the Effect of Nasal Insulin on Postprandial Glycemic Control in Type 2 Diabetic Patients

Completed · Phase 2

Conditions studied: Diabetes Mellitus

In brief

Insulin is a hormone which is produced by the human pancreas for the lowering of blood sugar. In patients who don't produce enough insulin, additional insulin must be given several times per day by injections. Nastech Pharmaceutical Company Inc. has developed a new insulin nasal spray, as a possible way to improve patient compliance with intensive insulin treatment plans. This study is being conducted to see how Nastech's insulin nasal spray affects post-meal glucose levels compared with rapid acting insulin (i.e., insulin aspart) in Type 2 diabetics who are already taking oral antidiabetic medications and/or insulin therapy. Insulin aspart is marketed as NovoLog® in the United States. The safety of insulin nasal spray and how well it is tolerated as compared to NovoLog will also be evaluated.

Key facts

Study ID

NCT00624767

Run by

Nastech Pharmaceutical Company, Inc.

People needed

18

Starts

2008-03-01

Expected to finish

2008-05-01

Last updated by the study team

2008-05-20

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Type 2 diabetes for at least 3 months
• Type 2 diabetics on oral antidiabetic medicines and/or insulin therapies

You may not qualify if…

• Patients taking intermediate acting insulin such as NPH
• Recurrent severe hypoglycemia
• Patients with late diabetic complications

Where it is running

• Diabetes and Glandular Disease Research Associates — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.